Dr Tripathi on the NEMIO Trial of Durvalumab Plus Chemo With/Without Tremelimumab in MIBC

Abhishek Tripathi, MD, discusses the phase 1/2 NEMIO trial of durvalumab/chemotherapy with/without tremelimumab in muscle-invasive bladder cancer.

Related Keywords

Abhishek Tripathi , ,Onclive Tv ,Urothelial Cancer ,Hase 3 Checkmate 901 Trial ,Nivolumab ,Gemcitabine ,Cisplatin ,